PO.IM01.12 · 免疫学

一种用于肝癌治疗的体内MAIT细胞激活与再生系统

An in vivo MAIT cell activation and rejuvenation systemfor liver cancer therapy

编号 4316 展板 20 时间 4/21 09:00–12:00 区域 Section 8 主讲 Yanruide Li
分会场 Immunomodulatory Agents
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Yan-Ruide Li1, Haochen Nan2, Zhengyao Shao3, Xinyuan Shen1, Lili Yang1

1Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA,2Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA,3Department of Pharmacology, University of California, San Diego, San Diego, CA

摘要 Abstract

中文摘要
黏膜相关恒定T(MAIT)细胞是富集于肝脏的非常规T细胞,具有强大的抗肿瘤潜力,然而在肝癌中它们数量减少且功能耗竭,从而限制了其治疗效果。为克服这些局限,我们开发了一种MAIT细胞激活与再生系统(MARS),这是一种仿生支架,经工程化设计可将MAIT激动剂5-OP-RU和IL-15直接递送至肝脏,促进MAIT细胞的激活、再生和细胞毒性功能。在离体条件下,MARS显著刺激来自肝癌患者外周血和肝组织的MAIT细胞,增强其效应功能和细胞毒性,同时减少耗竭。在体内,MARS高效定位于肝脏,在人肝癌异种移植小鼠模型中增强MAIT细胞的激活、扩增和杀伤肿瘤能力。重要的是,在人髓系细胞植入的小鼠模型中,MARS促进了肝脏MR1+肿瘤相关巨噬细胞的清除,进一步支持MAIT细胞的抗肿瘤活性。总之,通过其仿生设计和肝脏靶向的免疫调节作用,MARS为增强基于MAIT细胞的肝癌免疫治疗提供了一种高效而安全的策略。
查看英文原文 English abstract
Mucosal-associated invariant T (MAIT) cells are liver-enriched unconventional T cells with potent antitumor potential, yet in liver cancer they are numerically reduced and functionally exhausted, limiting their therapeutic efficacy. To overcome these limitations, we developed a MAIT cell activation and rejuvenation system (MARS), a biomimetic scaffold engineered to deliver MAIT agonist 5-OP-RU and IL-15 directly to the liver, promoting MAIT cell activation, rejuvenation, and cytotoxic function. Ex vivo , MARS significantly stimulated MAIT cells from liver cancer patient peripheral blood and liver tissues, enhancing their effector function and cytotoxicity while reducing exhaustion. In vivo , MARS efficiently localized to the liver, boosting MAIT cell activation, expansion, and tumor-killing capacity in human liver cancer xenograft mouse models. Importantly, in a human myeloid cell-engrafted mouse model, MARS facilitated the depletion of liver MR1 + tumor-associated macrophages, further supporting MAIT cell antitumor activity. Collectively, through its biomimetic design and liver-targeted immunomodulatory effects, MARS provides an efficient and safe strategy to enhance MAIT cell-based immunotherapy for liver cancer.
利益披露 Disclosure
Y. Li, None.. H. Nan, None.. Z. Shao, None.. X. Shen, None. L. Yang, AlzChem Scientific advisor. Amberstone Biosciences Scientific advisor. Appia Bio Stock.

← 返回 AACR 2026 检索